This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

BioMarin Doses First Patient In Phase 1/2 Trial With BMN 190 For The Treatment Of Neuronal Ceroid Lipofuscinosis Type 2, A Form Of Batten Disease

SAN RAFAEL, Calif., Sept. 23, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first patient in the Phase 1/2 trial for BMN 190, a recombinant human tripeptidyl peptidase 1 (rhTPP1) for the treatment of patients with neuronal ceroid lipofuscinosis type 2 (NCL-2), a form of Batten disease. This is the first time that a patient with Batten Disease has been treated with an enzyme replacement therapy in a clinical trial setting.

"This program is representative of the company's core competency of developing life-altering enzyme replacement therapies for serious unmet medical needs," said Hank Fuchs, M.D., Executive Vice President and Chief Medical Officer of BioMarin. "We are inspired and motivated by the patient and physician community and encouraged by the pharmacological activity demonstrated in preclinical models. We hope to leverage our expertise in enzyme replacement therapy development to deliver a viable treatment option to patients with this form of Batten Disease."

"The completion of dosing of the first patient in the trial of BMN190 marks the beginning of an important journey. This neurodegenerative disease of childhood is devastating for patients and families. While we hope to make a large difference in their outcome, we are moved and grateful for the support of affected families worldwide," said Angela Schulz, M.D. Ph.D., Children's Hospital, University Medical Center Hamburg-Eppendorf. "Clinical trials are the only means to ascertain whether the promise of this new therapeutic approach will be fulfilled. Without the families' selfless dedication to the important principles of science, this would not be possible."

"We are encouraged by this important milestone, and support the clinical trial process as the best way to bring much needed therapies to underserved patient populations," said Tracy VanHoutan, founder of the Noah's Hope Batten Disease research fund, and 2nd Vice President of the Batten Disease Support and Research Association, the largest organization in the world dedicated to family support and medical research in Batten Disease.

Stock quotes in this article: BMRN 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs